Geneos Wealth Management’s TG Therapeutics TGTX Stock Holding History

Geneos Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.7K	Sell	1,269 -900	-41%	-$36.8K	﹤0.01%	1350
2026 Q1	$72.1K	Hold	2,169	–	–	﹤0.01%	1293
2025 Q4	$64.7K	Hold	2,169	–	–	﹤0.01%	1300
2025 Q3	$78.4K	Hold	2,169	–	–	﹤0.01%	1208
2025 Q2	$78.1K	Buy	2,169 +1,446	+200%	+$53.8K	﹤0.01%	1357
2025 Q1	$28.5K	Hold	723	–	–	﹤0.01%	1764
2024 Q4	$21.8K	Buy	723 +300	+71%	+$8.61K	﹤0.01%	1690
2024 Q3	$9.89K	Hold	423	–	–	﹤0.01%	1846
2024 Q2	$7.53K	Hold	423	–	–	﹤0.01%	1618
2024 Q1	$6.43K	Hold	423	–	–	﹤0.01%	1661
2023 Q4	$7.22K	Hold	423	–	–	﹤0.01%	1635
2023 Q3	$3.54K	Hold	423	–	–	﹤0.01%	1834
2023 Q2	$10.5K	Hold	423	–	–	﹤0.01%	1569
2023 Q1	$6.36K	Sell	423 -477	-53%	-$7.25K	﹤0.01%	1672
2022 Q4	$10.6K	Buy	+900	New	+$6.53K	﹤0.01%	1515

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geneos Wealth Management's TGTX Position: Q2 2026 in Review

Geneos Wealth Management reduced its TG Therapeutics (TGTX) stake by 41% in Q2 2026, selling an estimated $36.8K and leaving 1,269 shares worth $69.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

Geneos Wealth Management first reported a position in TGTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $78.4K in Q3 2025. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Geneos Wealth Management held 1,269 shares of TG Therapeutics worth $69.7K as of Q2 2026.
Geneos Wealth Management sold 900 TG Therapeutics shares in Q2 2026, an estimated $36.8K.
TG Therapeutics made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #1350 holding.
Geneos Wealth Management first reported a position in TG Therapeutics in Q4 2022 and has held it in 15 quarters since.
Geneos Wealth Management's TG Therapeutics position peaked at $78.4K in Q3 2025.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.